Efficacy and safety of vitamin K plus sorafenib combination treatment against hepatocellular carcinoma-Open label, randomized, phase 2 study.

Haruna Yoshimichi; Inoue Atsuo

首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >Efficacy and safety of vitamin K plus sorafenib combination treatment against hepatocellular carcinoma-Open label, randomized, phase 2 study.

【24h】

Efficacy and safety of vitamin K plus sorafenib combination treatment against hepatocellular carcinoma-Open label, randomized, phase 2 study.

机译：维生素K加上索拉非尼蛋白联合治疗对肝细胞癌开放标签，随机，第2期研究的疗效和安全性。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Hepatology: Official Journal of the American Association for the Study of Liver Diseases》 |2017年第1期|共1页
作者
Haruna Yoshimichi; Inoue Atsuo;
展开▼
作者单位

Osaka Gen Med Ctr Dept Gastroenterol &

Hepatol Osaka Japan;

Osaka Gen Med Ctr Dept Gastroenterol &

Hepatol Osaka Japan;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of vitamin K plus sorafenib combination treatment against hepatocellular carcinoma-Open label, randomized, phase 2 study. [J] . Haruna Yoshimichi, Inoue Atsuo Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2017,第Suppla1期

机译：维生素K加上索拉非尼蛋白联合治疗对肝细胞癌开放标签，随机，第2期研究的疗效和安全性。
2. A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma [J] . D. H. Palmer, Y. T. Ma, M. Peck-Radosavljevic, British Journal of Cancer . 2018,第9期

机译：一项多中心，开放标签，I期/随机II期研究，用于评估nintedanib与sorafenib在欧洲晚期肝细胞癌患者中的安全性，药代动力学和疗效
3. A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma [J] . D. H. Palmer, Y. T. Ma, M. Peck-Radosavljevic, British Journal of Cancer . 2018,第9期

机译：一项多中心，开放标签，I期/随机II期研究，用于评估nintedanib与sorafenib在欧洲晚期肝细胞癌患者中的安全性，药代动力学和疗效
4. Magnetically Targeted Delivery of Sorafenib Through Magnetic Solid Lipid Nanoparticles Towards Treatment of Hepatocellular Carcinoma [C] . F. Vischio, N. Depalo, R. M. Iacobazzi, NATO Advanced Study Institute on Detection, Diagnosis and Health Concerns of Toxic Chemical and Biological Agents . 2020

机译：通过磁性固体脂质纳米粒子致磁性固体脂质纳米粒子对肝细胞癌治疗的磁性靶向递送
5. Development and impact of a food label education intervention on food label knowledge, self-efficacy and stage of change among Latinos: A randomized community trial. [D] . Haldeman, Lauren Ann. 2001

机译：食品标签教育干预措施对拉丁裔拉丁美洲人食品标签知识，自我效能感和变化阶段的发展及其影响：一项随机社区试验。
6. Efficacy and safety of sorafenib plus vitamin K treatment for hepatocellular carcinoma: A phase II randomized study [O] . Yoshimichi Haruna, Takayuki Yakushijin, Seiichi Kawamoto 2021

机译：Sorafenib Plus维生素K治疗治疗肝细胞癌的功效和安全性：A II期随机研究
7. Efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma in a phase 3, randomized, open-label, multicenter study - Trial in progress [O] . S. Qin, R. Finn, M. Kudo, 2018

机译：Tislelizumab的疗效和安全性，抗PD-1抗体，索拉非尼作为患有第3阶段晚期肝细胞癌患者的一线治疗，随机，开放标签，多中心研究 - 正在进行试验

Efficacy and safety of vitamin K plus sorafenib combination treatment against hepatocellular carcinoma-Open label, randomized, phase 2 study.

著录项

相似文献

相关主题

期刊订阅